New PharmaLinea lower back pain supplement tested in clinical trial

Photo © adobestock.com/Yeti Studio

In a September 18, 2024, press release, PharmaLinea, (Ljubljana, Slovenia), announced the results of a clinical trial testing the effectiveness of its >Your< Back Pain Capsules in reducing back pain when added the physical therapy. Back pain, explained the press release, affects up to 80% of people at some points in their lifetime. The >Your< Back Pain Capsules were created from PharmaLinea’s proprietary complex, Qspine—which consists of nucleotide complex and vitamins B1, B6, B12, and D3—to target neuronal damage. The prospective, double-blind, randomized study, “Quality of Life in Patients with Lumbosacral Radicular Syndrome and Complete Rehabilitation Program (PRISUM PHSD/1/2022),” was published in April 2024 in Family Medicine and Primary Care: Open Access.

For the trial, which lasted three months, 247 participants were split into two groups, one group treated with physical rehabilitation with the addition of >Your< Back Capsules daily, and the other group treated with physical rehabilitation and a placebo. According to the press release, compared to the 92 patients in the control group, the 151 patients in the test group experienced overall:

• 51% improvement in the pain-relieving effect of physical therapy (according to the SF-MPQ scale)
• 52% increase in physical therapy's improvement of mobility (according to the Finger-to-floor distance test)
• Improvement in pain severity according to the Visual Analogue Scale (VAS)
• Improvement in independent living index according to the Activities of Daily Living (ADL) scale
• Improvement in radicular syndrome test, Schober test, and Myofascial syndrome test

Additionally, the >Your< Back Pain Capsules did not cause adverse effects and did not have a risk of addiction, unlike analgesics, a common treatment for back pain.

“Low back pain is the leading cause of disability worldwide,” stated stated Maja Orešnik, Science and Research Director at PharmaLinea, in the press release. “The affected typically seek analgesic drugs to alleviate their symptoms. But for neuropathic pain, which is very common in low back pain, analgesics are often unable to provide the side effects-free, effective relief that consumers seek. This is the goal we aimed to support with our product and the presented clinical study. We are very impressed with the robustness of the results and the product’s efficacy. The results stand out due to the high values of the shown differences, such as 51% higher improvement. These differences were statistically significant across a number of different questionnaires and tests, such as the VAS scale, SF-MPQ, Schober test, and so forth. Importantly, the product was compared against physical therapy and not just placebo capsules, which makes effects more difficult to show, and results even more solid.”

Results from the clinical trial will be presented in an October 2 webinar from PharmaLinea with speakers Maja Orešnik and Dr. Rodica Traistaru, Doctor of Medicine at UMF Craiova, Discipline of Physical and Rehabilitation Medicine.

Last month, PharmaLinea also introduced a new, clinically studied joint support product, as well as line extensions to its >Your< Prediabetiq and >Your< Iron product lines.

References

1. Trăistaru, MR.; Kamal, D.; Alexandru, DO.; Kamal, AM.; Constantin, K. Quality of Life in Patients with Lumbosacral Radicular Syndrome and Complete Rehabilitation Program (PRISUM PHSD/1/2022). J Family Med Prim Care Open Acc. 2024. https://www.gavinpublishers.com/article/view/quality-of-life-in-patients-with-lumbosacral-radicular-syndrome-and-complete-rehabilitation-program-prisum-phsd12022 (accessed Sept 26, 2024).
2. PharmaLinea, back pain clinical trial. https://pharmalinea.com/news/webinar-back-pain-clinical-trial/ (accessed Sept 26, 2024).